Complete financial analysis of Orgenesis Inc. (ORGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orgenesis Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Inbound Tech Inc. (7031.T) Income Statement Analysis – Financial Results
- Iron Force Industrial Co., Ltd. (2228.TW) Income Statement Analysis – Financial Results
- Ora Banda Mining Limited (OBM.AX) Income Statement Analysis – Financial Results
- HOB Co.,Ltd. (1382.T) Income Statement Analysis – Financial Results
- Royal Orchid Hotels Limited (ROHLTD.BO) Income Statement Analysis – Financial Results
Orgenesis Inc. (ORGS)
About Orgenesis Inc.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 530.00K | 36.03M | 35.50M | 7.65M | 33.26M | 18.66M | 10.09M | 6.40M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.26M | 20.44M | 28.16M | 30.62M | 18.12M | 10.70M | 6.81M | 7.66M | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00 |
| Gross Profit | -5.73M | 15.59M | 7.34M | -22.97M | 15.14M | 7.96M | 3.28M | -1.26M | -906.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00 |
| Gross Profit Ratio | -1,080.19% | 43.26% | 20.68% | -300.13% | 45.53% | 42.65% | 32.53% | -19.70% | -30.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.09M | 6.01M | 36.64M | 83.99M | 12.46M | 6.46M | 2.48M | 2.16M | 1.07M | 1.69M | 1.64M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.62M | 16.16M | 15.40M | 19.35M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 0.00 |
| Selling & Marketing | 464.00K | -566.00K | -687.00K | -380.00K | 1.15M | 1.21M | 599.00K | 397.00K | 326.00K | 144.00K | 187.83K | 140.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.62M | 16.16M | 14.71M | 18.97M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 3.00K |
| Other Expenses | 0.00 | 788.00K | -1.33M | 474.00K | 2.04M | -1.02M | 1.63M | 2.12M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Operating Expenses | 45.76M | 22.95M | 50.02M | 103.43M | 39.74M | 22.06M | 14.80M | 10.23M | 6.31M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.00K |
| Cost & Expenses | 52.01M | 43.39M | 50.02M | 103.43M | 57.86M | 32.75M | 21.60M | 17.88M | 10.19M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.50K |
| Interest Income | 0.00 | 1.82M | 943.00K | 1.25M | 498.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.17M | 1.82M | 1.29M | 1.06M | 461.00K | 2.75M | 1.23M | 689.00K | 696.00K | 691.09K | 172.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.56M | 1.98M | 1.86M | 1.44M | 3.81M | 2.62M | 2.60M | 2.92M | 1.99M | 4.55K | 3.26K | 1.41K | 0.00 | 15.00K | 0.00 | 0.00 |
| EBITDA | -60.72M | -8.30M | -15.72M | -94.21M | -18.91M | -12.39M | -9.85M | -9.04M | -2.64M | -4.80M | -5.36M | -5.00M | -72.35K | -6.17K | -25.65K | -3.50K |
| EBITDA Ratio | -11,456.23% | -19.15% | -39.00% | -1,244.08% | -62.73% | -65.47% | -100.96% | -135.77% | -175.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -53.64M | -7.37M | -42.68M | -95.78M | -24.60M | -14.65M | -11.23M | 11.28M | -7.21M | -4.58M | -5.46M | -4.99M | -72.35K | -21.17K | -25.65K | -3.50K |
| Operating Income Ratio | -10,120.00% | -20.45% | -120.22% | -1,251.71% | -73.98% | -78.53% | -111.31% | 176.29% | -242.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.81M | -1.85M | -1.15M | -1.63M | -47.00K | -2.83M | -3.66M | -1.26M | 1.85M | -927.10K | -78.66K | -519.21K | 0.00 | -15.00K | 0.00 | 0.00 |
| Income Before Tax | -64.44M | -11.96M | -17.95M | -96.74M | -25.48M | -17.77M | -13.68M | -10.74M | -5.36M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Income Before Tax Ratio | -12,159.43% | -33.20% | -50.56% | -1,264.19% | -76.61% | -95.24% | -135.56% | -167.91% | -180.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 473.00K | 209.00K | 108.00K | -1.61M | 563.00K | 1.34M | -1.31M | -1.55M | -900.00K | 691.09K | 172.51K | 9.58K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -55.36M | -12.17M | -18.06M | -95.13M | -26.04M | -18.29M | -12.37M | -9.19M | -4.46M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Net Income Ratio | -10,445.47% | -33.78% | -50.87% | -1,243.17% | -78.30% | -98.05% | -122.58% | -143.72% | -150.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.28 | -1.08 | -0.96 | -1.22 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.27 | -1.08 | -0.94 | -1.21 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.68M | 8.52M | 4.65M | 4.51M | 4.20M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
| Weighted Avg Shares Out (Dil) | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.71M | 8.52M | 4.74M | 4.56M | 4.21M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a...
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive...
Orgenesis Provides Business Update for the First Quarter of 2024
Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera
Orgenesis Provides Year End Business Update
M ajor transformation underway commencing with recent acquisition reasserting full ownership and control over Octomera
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an...
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit...
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that the Company has been awarded a €1.5 million grant from the Walloon...
Orgenesis Inc. Announces $2.3 Million Private Placement
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement with certain...
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company's consortium was awarded a €2.0 million grant from the Walloon...
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an...
Source: https://incomestatements.info
Category: Stock Reports